SCHEMBL20970352

SCHEMBL20970352

CCCC(C)(C)c1ccc2[nH]ncc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 3/20 0.49
ROCK2 O75116 4/20 0.45
ROCK1 Q13464 3/20 0.45
METAP2 P50579 2/20 0.45
CSNK2A1 P68400 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
HIF1A Q16665 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
IDH1 O75874 1/20 0.44
TRPA1 O75762 3/20 0.43
GSK3B P49841 3/20 0.43
JAK2 O60674 2/20 0.43
PIM1 P11309 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19513331 0.88 METAP2 (0.57) NOS1METAP2KDM4EMEN1ALDH1A1
SCHEMBL11888515 0.87 NOS1 (0.51) NOS1ROCK2ROCK1METAP2CSNK2A1
SCHEMBL22251897 0.84 NOS1 (0.43) NOS1ROCK2ROCK1METAP2CSNK2A1
SCHEMBL13486198 0.81 NOS1 (0.47) NOS1ROCK2ROCK1METAP2CSNK2A1
SCHEMBL762038 0.80 IDH1 (0.55) NOS1ROCK2ROCK1METAP2CSNK2A1
SCHEMBL20618759 0.79 IDH1 (0.41) NOS1ROCK2ROCK1METAP2CSNK2A1
SCHEMBL26026447 0.79 TRPA1 (0.46) NOS1ROCK2ROCK1METAP2CSNK2A1
SCHEMBL6090446 0.78 ROCK1 (0.47) NOS1ROCK2ROCK1METAP2CSNK2A1
SCHEMBL23136093 0.77 METAP2 (0.54) NOS1ROCK2ROCK1METAP2CSNK2A1
SCHEMBL26121286 0.77 ROCK1 (0.52) NOS1ROCK2ROCK1METAP2CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210130361-A1 TGF-ß INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2021-05-06 US disclosed
US-10822312-B2 Substituted quinazoline compounds and methods of use ARAXES PHARMA LLC (US) 2020-11-03 US disclosed
US-20190127336-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE ARAXES PHARMA, LLC 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127336-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE NRAS, KRAS, HRAS NOS1 4504/4885ROCK2 949/4885ROCK1 1351/4885
US-20210130361-A1 TGF-ß INHIBITORS TGFBR1, TGFBR2, TGFB1 NOS1 135/4885ROCK2 898/4885ROCK1 502/4885
US-10822312-B2 Substituted quinazoline compounds and methods of use NRAS, KRAS, HRAS NOS1 4386/4885ROCK2 1390/4885ROCK1 1813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.